United States Biologics and Biosimilars Treatment Market 2017-2021

Dublin, Oct. 20, 2017 (GLOBE NEWSWIRE) -- The "The Future of the U.S. Biologics and Biosimilars Treatment Market for Psoriasis" report has been added to Research and Markets' offering.

Focus Areas

• Psoriasis disease deep dive, in-depth epidemiology, treatment guidelines, and assessment tools
• Revenue analyses by drug class and the leading brands
• Current and forecast market sales of Biologics and Biosimilars
• Leading Players Analyses, Company Strategy and Outlook
• Detailed Late-stage pipeline intelligence and the projected peak sales contribution
• Market & R&D Trends, Drivers, challenges and the opportunities facing the sector

Major Takeaways

The U.S. psoriasis treatment market for Biologics and Biosimilars was estimated at $6.6bn in 2016 is projected to almost double during the forecast period to reach $12.9bn in 2021 driven by safety and efficacy improvements of the new generation biologics.

The psoriasis treatment market is dominated by topical agents and photo therapy for the non-severe forms (mainly corticosteroids), but mild to severe forms are treated with systemic agents. The psoriasis treatment market is dominated by topical agents and photo therapy for the non-severe forms (mainly corticosteroids), but mild to severe forms are treated with systemic agents.

Driven by improved efficacy, the first group of anti TNF treatments led by Enbrel, Humira and Remicade made strong penetration into the psoriasis market. However the emergence of the IL-17 inhibitor class driven by Novartis' Cosentyx and Eli Lilly's Talz have set a new benchmark for efficacy in moderate to severe psoriasis treatment with potential for safety improvement in comparison to the anti TNF drugs given their greater specificity in immune Suppression. MP Advisors expect the TNF class of drugs to lose share to the newer brands with improved clinical profiles in Psoriasis.

The market growth in psoriasis is driven by an upsurge in demand from new therapies in moderate to severe patient population which overshadows reduced pricing of branded TNF-a inhibitor and recent biosimilar launches. The psoriasis treatment market is facing increasing competitive pressure from a wave of biosimilar launches such as biosimilars of Janssen's Remicade, and Amgen's Enbrel with the impact of the headwinds expected to be more pronounced in the next few years.

Stelara has been an important growth driver of Janssen's immunology franchise in recent years, with overall global sales doubling from $1.5bn in 2013 to more than $3.2bn in 2016. However Stelara has started to face steeper competition from the IL-17 drug class. A new head-to-head study report IL-17 products to demonstrate superior efficacy to Stelara for psoriasis.

Key Topics Covered:

1. Psoriasis Market Overview
1.1. Disease background
1.2. Types of psoriasis
1.2.1. Plaque psoriasis
1.2.2. Guttate psoriasis
1.2.3. Inverse (flexural) psoriasis
1.2.4. Pustular psoriasis
1.2.5. Erythrodermic psoriasis
1.3. Pathophysiology
1.4. Etiology
1.4.1. Environmental factors
1.4.2. Genetic factors
1.4.3. Immunologic factors
1.5. Risk factors and co-morbidities
1.6. Epidemiology
1.7. Treatment options
1.7.1. Phototherapy
1.7.2. Topical treatments
1.7.3. Conventional systemic agents
1.7.4. Other systemic drugs
1.7.5. Biologics
1.8. Treatment Guidelines
1.8.1. Mild to moderate Psoriasis
1.8.2. Moderate Psoriasis
1.8.3. Moderate -to-severe psoriasis
1.8.4. Severe psoriasis

2. Psoriasis Treatment Market for Biologics
2.1. Introduction and Market Overview
2.2. Revenue Analysis for Biologics in the U.S.
2.3. Key marketed products for psoriasis treatment
2.3.1. Remicade (infliximab; Janssen)
2.3.2. Humira (adalimumab; AbbVie)
2.3.3. Stelara (ustekinumab; Janssen)
2.3.4. Cosentyx (secukinumab; Novartis)
2.3.5. Taltz (ixekizumab; Lilly)
2.3.6. Siliq (brodalumab; Valeant)
2.3.7. Tremfya (guselkumab; Janssen)
2.4. Key pipeline products for psoriasis treatment
2.4.1. Tildrakizumab; Merck / Sun Pharma
2.4.2. Cimzia (certolizumab pegol; UCB/Dermira Pharmaceuticals)
2.4.3. Risankizumab; AbbVie/Boehringer Ingelheim
2.5. Growth Drivers and Resistors for Biologics
2.5.1. Growth Drivers:
2.5.2. Resistors
2.6. Competitive Landscape - Approved Products
2.7. Competitive Landscape - Pipeline Products

3. Psoriasis Market for Biosimilars
3.1. Introduction and Market Overview
3.2. Approved biosimilars
3.2.1. Approved biosimilars in the U.S.
3.2.2. Revenue Analysis for Biosimilars in U.S.
3.2.3. Approved biosimilars in the EU
3.3. Pipeline Analysis
3.3.1. Clinical development - Humira (adalimumab) biosimilars
3.3.2. Clinical development - Enbrel (etanercept) biosimilars
3.3.3. Clinical development - Remicade (infliximab) biosimilars
3.4. Biosimilars deals and partnerships
3.5. Growth Drivers and Resistors for Biosimilars
3.5.1. Growth Drivers
3.5.2. Resistors
3.6. Competitive Landscape - Approved Biosimilars in the U.S. and EU
3.7. Competitive Landscape - TNF a Inhibitors Biosimilars Pipeline

For more information about this report visit https://www.researchandmarkets.com/research/ttvdwg/the_future_of_the

                    
                    
                    CONTACT: Research and Markets
                             Laura Wood, Senior Manager
                             press@researchandmarkets.com
                             For E.S.T Office Hours Call 1-917-300-0470
                             For U.S./CAN Toll Free Call 1-800-526-8630
                             For GMT Office Hours Call +353-1-416-8900
                             Related Topics: Biopharmaceuticals , Biosimilars and Biosuperiors, Psoriasis Drugs